Merck & Co., Inc. (MRK) has been one of the standout large-cap healthcare stories of the past year, powered by an oncology pipeline that analysts now believe could offset the looming loss of exclusivity on its flagship immunotherapy. With the stock trading in the mid-$140s and a 52-week high near $157, investors are increasingly asking whether the shares can make a run toward $180 — a level that sits near the top of the current Wall Street price-target range.
Merck has climbed sharply in 2026, gaining more than 40% year to date at its recent peak, after a Phase 3 melanoma trial conducted with MRNA (Moderna) met its primary endpoint. The stock surged more than 12% in a single session on that news, driving a wave of price-target increases across Wall Street. Several firms — including BMO, Argus, Wells Fargo, and HSBC — lifted their objectives into the $170–$172 range, while a handful of analysts now carry targets of $175 to $186. In that context, $180 represents a natural psychological milestone that would confirm the bull case that Merck can successfully transition beyond its dependence on a single drug.
Merck is a global biopharmaceutical company whose portfolio spans oncology, vaccines, infectious disease, cardiometabolic treatments, and animal health. Its best-known products are Keytruda, the cancer immunotherapy that generated over $30 billion in 2025 sales and accounts for nearly half of total revenue, and Gardasil, the human papillomavirus (HPV) vaccine. The company has also been active on the deal front, completing acquisitions of Cidara Therapeutics, Terns Pharmaceuticals, and TARGAN to deepen its pipeline in antivirals, hematology, and animal health.
The most important catalyst behind the recent rally is the personalized cancer vaccine program known as INTerpath, developed in partnership with Moderna. In high-risk melanoma patients, combining the therapy with Keytruda significantly delayed cancer recurrence compared with Keytruda alone. Merck and Moderna are now studying the approach across nine Phase 2 and Phase 3 trials spanning lung, bladder, and kidney cancers. Analysts such as BMO have suggested the franchise could eventually add billions in annual revenue if it succeeds across additional tumor types.
Beyond the cancer vaccine, Merck's pipeline includes sacituzumab tirumotecan (Sac-TMT), an antibody-drug conjugate with potential in multiple solid tumors, and Winrevair, a cardiometabolic treatment whose sales have been growing rapidly. A series of late-stage readouts expected over the coming quarters could provide the kind of data-driven momentum that historically supports further multiple expansion in biopharma stocks.
The primary obstacle is the Keytruda patent cliff. Key patents on Merck's top-selling drug begin expiring in 2028, which could open the door to biosimilar competition and erode the revenue stream that currently underpins the company's profitability. That concentration risk has prompted caution from firms like RBC Capital and UBS, which downgraded the stock to neutral or sector-perform ratings even while raising their targets to $150, arguing that the shares already reflect a great deal of optimism.
Valuation is a related concern. Following the rally, Merck trades at a stretched earnings multiple by its own historical standards, leaving limited room for error if upcoming clinical trials disappoint. Declining Gardasil volumes in China, potential drug-pricing legislation, and rising research-and-development costs tied to acquisitions also weigh on the near-term earnings picture.
The consensus rating on Merck remains a "Moderate Buy," with an average 12-month price target near $150. Targets span a wide range, from a low around $105 to a high of roughly $186. The $180 objective sits comfortably above the consensus but below the most optimistic individual forecasts, suggesting it is attainable only if the pipeline narrative continues to strengthen.
From a technical analysis perspective, the stock must first reclaim and hold above its 52-week high near $157. That area represents a meaningful supply zone, and a decisive breakout above it would clear the path toward $170 and eventually $180. On the downside, the $130–$134 band — where the stock consolidated before its latest advance — serves as the most important support level investors should monitor.
For traders looking to track momentum in names like Merck alongside the broader market, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to stay ahead of shifting conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify changing market trends more efficiently. Exploring the tool can help investors complement their own research with an automated, round-the-clock perspective.
A move to $180 is ambitious but not unrealistic for Merck. The strongest argument in favor is the company's rapidly expanding oncology pipeline, anchored by the Moderna cancer-vaccine program and a slate of late-stage readouts that could meaningfully de-risk the post-Keytruda era. The biggest counterweight is valuation and the structural overhang of the Keytruda patent expiry, which keeps cautious analysts anchored near $150. Investors should watch for a sustained breakout above the $157 high, additional positive trial data, and any signs that new products are accelerating revenue growth before concluding that $180 is within reach. As with any single-name bet, the outcome depends on clinical execution as much as on market sentiment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % |
|---|---|---|
| MRK | 100% | -2.66% |
| MRK (2 stocks) | 99% Closely correlated | -1.68% |
| immune (10 stocks) | 81% Closely correlated | -0.24% |
| covid-19 vaccine (6 stocks) | 75% Closely correlated | +0.01% |
| gene therapy (7 stocks) | 65% Loosely correlated | -0.10% |
| human (13 stocks) | 63% Loosely correlated | -4.57% |
More | ||